CYFRA21-1 can predict the sensitivity to chemoradiotherapy of non-small-cell lung carcinoma

Wang, Juan; Yi, Yan; Li, Baosheng; Wang, Zhongtang; Sun, Hao; Zhang, Peiliang

doi:10.3109/1354750x.2010.504308

Cited by 16 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cases of advanced lung cancer showed a statistically highly significant increase in CK19 than benign lung disease ( p < 0.001). This result was in concordance with results reported by Weiskopf et al [4], Ebert et al [5], Paone et al [6], Krismann et al [7], Qu et al [16], and Wang et al [17]. …”

Section: Discussionsupporting

confidence: 93%

ecancermedicalscience

Bastawisy

Azzouny

Mohammed

et al.

View full text Add to dashboard Cite

Introduction:Lung cancer is one of the most lethal malignancies; however, no serum marker has been routinely recommended until now.Methods:This is a prospective case control study including two groups of patients: Group I—patients with advanced lung cancer and Group II—patients with benign lung disease as control. Serum cytokeratin 19 (CK19) fragment levels were measured at baseline by real-time polymerase chain reaction before first-line chemotherapy. The CK19 cut-off taken was 15-cycle threshold. The primary end point was the comparison of high CK19 in cases and controls. The secondary end point was the correlation between high CK19 and progressive disease (PD), progression-free survival, and overall survival (OS) in advanced lung cancer patients.Results:A total of 30 patients with advanced lung cancer (16 non-small and 14 small cell lung cancer) and 15 patients with benign lung disease were included and followed up during the period from October 2008 to October 2011 with median follow-up of one and half years. High CK19 was found in 90% of lung cancer cases as compared with 7% in controls (p < 0.001). High CK19 was found in all cases showing PD (p = 0.04). One-year OS in high CK was 61% as compared with 33% in normal CK (p = 0.1).Conclusion:Serum CK19 fragment is a potential diagnostic and prognostic marker for advanced lung cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

ecancermedicalscience

Bastawisy

Azzouny

Mohammed

et al.

View full text Add to dashboard Cite

show abstract

“…Serum CYFRA21-1 level has also been shown to predict treatment effectiveness and prognosis in patients treated with surgery, [13,14] chemotherapy, [15–17] targeted therapy, [18–20] and concurrent chemoradiation. [21] Previous studies of the association of change in serum CYFRA21-1 with response to chemotherapy, which focused on synchronous or early prediction of OR, found that it did have predictive value. [12–25] A few investigations have reported the predictive value of change in serum CYFRA21-1 with DC after the second cycle of chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…About one to two million people die from lung cancer every year worldwide. Lung cancer causes more deaths than the other three most common cancers combined, i.e., colon, breast and prostate (1,2). In an attempt to describe human lung cancer, many studies have concentrated on enzyme activities (3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

“…In addition, serum tumour markers are not useful in lung cancer diagnosis (1). The diagnosis of lung cancer is based on the histological and cytological examination of material usually obtained by bronchoscopy (endobronchial biopsies, washings, and brushings) (19).…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Utility of Adenosine Deaminase in Serum and Bronchoalveolar Lavage Fluid for Screening Lung Cancer in Western Iran

Nikkhoo¹,

Sigari²,

Ghaderi³

et al. 2013

Journal of Medical Biochemistry

View full text Add to dashboard Cite

SummaryBackground: This study aimed to determine adenosine deaminase (ADA) activity as a possible screening tool in lung cancer patients. Methods: Blood samples were collected from 30 subjects with positive pathological tests and 62 patients with negative pathological tests as a control group. The enzymatic activity of total ADA and its isoenzymes was determined. Results: tADA and ADA2 isoenzyme activity was significantly higher in cancerous patients compared to benign controls in serum and BAL fluid. Using a cut-off level of respectively 35.22 U/L and 31.80 U/L for BAL total ADA and ADA2, sensitivity and specificity were 100% and 81% for total ADA and 95% and 98% for ADA2. Conclusions: Adenosine deaminase may play important roles in the pathophysiology of lung cancer and because of its

show abstract

CYFRA21-1 can predict the sensitivity to chemoradiotherapy of non-small-cell lung carcinoma

Abstract: CYFRA21-1 may be a reliable surrogate marker of CRT efficacy in patients with NSCLC.

Cited by 16 publications

References 25 publications

ecancermedicalscience

ecancermedicalscience

CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer

Diagnostic Utility of Adenosine Deaminase in Serum and Bronchoalveolar Lavage Fluid for Screening Lung Cancer in Western Iran

Contact Info

Product

Resources

About